S&P 500   3,900.11 (-0.60%)
DOW   31,245.92 (-0.78%)
QQQ   290.59 (-0.19%)
AAPL   137.22 (-2.56%)
MSFT   252.86 (-0.48%)
FB   191.67 (-0.30%)
GOOGL   2,210.57 (-1.23%)
AMZN   2,157.43 (+0.71%)
TSLA   709.49 (-0.05%)
NVDA   172.49 (+1.84%)
BABA   88.33 (+1.17%)
NIO   16.69 (+5.43%)
AMD   98.02 (+1.81%)
CGC   5.91 (+5.72%)
MU   69.76 (-1.82%)
T   20.13 (-0.49%)
GE   75.69 (+0.65%)
F   12.93 (+1.17%)
DIS   103.51 (-0.76%)
AMC   12.79 (+0.24%)
PFE   50.43 (+0.06%)
PYPL   81.09 (+5.07%)
NFLX   184.08 (+3.89%)
S&P 500   3,900.11 (-0.60%)
DOW   31,245.92 (-0.78%)
QQQ   290.59 (-0.19%)
AAPL   137.22 (-2.56%)
MSFT   252.86 (-0.48%)
FB   191.67 (-0.30%)
GOOGL   2,210.57 (-1.23%)
AMZN   2,157.43 (+0.71%)
TSLA   709.49 (-0.05%)
NVDA   172.49 (+1.84%)
BABA   88.33 (+1.17%)
NIO   16.69 (+5.43%)
AMD   98.02 (+1.81%)
CGC   5.91 (+5.72%)
MU   69.76 (-1.82%)
T   20.13 (-0.49%)
GE   75.69 (+0.65%)
F   12.93 (+1.17%)
DIS   103.51 (-0.76%)
AMC   12.79 (+0.24%)
PFE   50.43 (+0.06%)
PYPL   81.09 (+5.07%)
NFLX   184.08 (+3.89%)
S&P 500   3,900.11 (-0.60%)
DOW   31,245.92 (-0.78%)
QQQ   290.59 (-0.19%)
AAPL   137.22 (-2.56%)
MSFT   252.86 (-0.48%)
FB   191.67 (-0.30%)
GOOGL   2,210.57 (-1.23%)
AMZN   2,157.43 (+0.71%)
TSLA   709.49 (-0.05%)
NVDA   172.49 (+1.84%)
BABA   88.33 (+1.17%)
NIO   16.69 (+5.43%)
AMD   98.02 (+1.81%)
CGC   5.91 (+5.72%)
MU   69.76 (-1.82%)
T   20.13 (-0.49%)
GE   75.69 (+0.65%)
F   12.93 (+1.17%)
DIS   103.51 (-0.76%)
AMC   12.79 (+0.24%)
PFE   50.43 (+0.06%)
PYPL   81.09 (+5.07%)
NFLX   184.08 (+3.89%)
S&P 500   3,900.11 (-0.60%)
DOW   31,245.92 (-0.78%)
QQQ   290.59 (-0.19%)
AAPL   137.22 (-2.56%)
MSFT   252.86 (-0.48%)
FB   191.67 (-0.30%)
GOOGL   2,210.57 (-1.23%)
AMZN   2,157.43 (+0.71%)
TSLA   709.49 (-0.05%)
NVDA   172.49 (+1.84%)
BABA   88.33 (+1.17%)
NIO   16.69 (+5.43%)
AMD   98.02 (+1.81%)
CGC   5.91 (+5.72%)
MU   69.76 (-1.82%)
T   20.13 (-0.49%)
GE   75.69 (+0.65%)
F   12.93 (+1.17%)
DIS   103.51 (-0.76%)
AMC   12.79 (+0.24%)
PFE   50.43 (+0.06%)
PYPL   81.09 (+5.07%)
NFLX   184.08 (+3.89%)
NASDAQ:BOLT

Bolt Biotherapeutics (BOLT) Stock Forecast, Price & News

$1.64
+0.07 (+4.46%)
(As of 05/19/2022 01:36 PM ET)
Add
Compare
Today's Range
$1.57
$1.65
50-Day Range
$1.41
$3.11
52-Week Range
$1.39
$19.79
Volume
2,104 shs
Average Volume
342,406 shs
Market Capitalization
$61.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.06
30 days | 90 days | 365 days | Advanced Chart
Receive BOLT News and Ratings via Email

Sign-up to receive the latest news and ratings for Bolt Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Bolt Biotherapeutics logo

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.

Headlines

Bolt Biotherapeutics (NASDAQ:BOLT) Price Target Cut to $5.00
Bolt Biotherapeutics (NASDAQ:BOLT) PT Lowered to $13.00
Bolt Biotherapeutics, Inc. (BOLT)
Bolt Biotherapeutics Stock Halves on Mediocre Trial Data
Why Bolt Biotherapeutics Stock Crashed Today
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:BOLT
CUSIP
09769810
Fax
N/A
Employees
91
Year Founded
N/A

Sales & Book Value

Annual Sales
$1.26 million
Book Value
$6.10 per share

Profitability

Net Income
$-98.59 million
Pretax Margin
-4,718.52%

Debt

Price-To-Earnings

Miscellaneous

Free Float
35,561,000
Market Cap
$61.45 million
Optionable
Not Optionable

Company Calendar

Last Earnings
3/30/2022
Today
5/19/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.16 out of 5 stars

Medical Sector

403rd out of 1,418 stocks

Pharmaceutical Preparations Industry

166th out of 677 stocks

Analyst Opinion: 3.4Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -













Bolt Biotherapeutics (NASDAQ:BOLT) Frequently Asked Questions

Is Bolt Biotherapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bolt Biotherapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Bolt Biotherapeutics stock.
View analyst ratings for Bolt Biotherapeutics
or view top-rated stocks.

Are investors shorting Bolt Biotherapeutics?

Bolt Biotherapeutics saw a increase in short interest in April. As of April 30th, there was short interest totaling 1,620,000 shares, an increase of 40.9% from the April 15th total of 1,150,000 shares. Based on an average trading volume of 236,300 shares, the days-to-cover ratio is currently 6.9 days. Currently, 7.7% of the company's shares are short sold.
View Bolt Biotherapeutics' Short Interest
.

When is Bolt Biotherapeutics' next earnings date?

Bolt Biotherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Bolt Biotherapeutics
.

How were Bolt Biotherapeutics' earnings last quarter?

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) released its quarterly earnings results on Wednesday, March, 30th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.81) by $0.08.
View Bolt Biotherapeutics' earnings history
.

What price target have analysts set for BOLT?

4 brokerages have issued 12 month target prices for Bolt Biotherapeutics' stock. Their forecasts range from $5.00 to $45.00. On average, they expect Bolt Biotherapeutics' share price to reach $24.00 in the next twelve months. This suggests a possible upside of 1,363.4% from the stock's current price.
View analysts' price targets for Bolt Biotherapeutics
or view top-rated stocks among Wall Street analysts.

Who are Bolt Biotherapeutics' key executives?
Bolt Biotherapeutics' management team includes the following people:
  • Dr. Randall C. Schatzman, CEO & Director (Age 67, Pay $830.67k)
  • Dr. Edgar G. Engleman M.D., Founder & Independent Director (Age 76, Pay $31.58k)
  • Mr. William P. Quinn, Chief Financial Officer (Age 51, Pay $563.68k) (LinkedIn Profile)
  • Mr. Grant Yonehiro C.F.A., M.B.A., Chief Bus. Officer (Age 58, Pay $519.98k)
  • Dr. Edith A. Perez M.D., Chief Medical Officer (Age 65, Pay $627.32k)
  • Dr. David Dornan Ph.D., Advisor (Age 44, Pay $580.08k)
  • Ms. Karen L. Bergman, VP of Communications & Investor Relations
  • Mr. Wesley Burwell, VP & Head of HR
What other stocks do shareholders of Bolt Biotherapeutics own?
When did Bolt Biotherapeutics IPO?

(BOLT) raised $150 million in an IPO on Friday, February 5th 2021. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Stifel and Guggenheim Securities served as the underwriters for the IPO.

What is Bolt Biotherapeutics' stock symbol?

Bolt Biotherapeutics trades on the NASDAQ under the ticker symbol "BOLT."

Who are Bolt Biotherapeutics' major shareholders?

Bolt Biotherapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.30%), Eventide Asset Management LLC (2.29%), Vanguard Group Inc. (2.26%), Renaissance Technologies LLC (0.77%), Northern Trust Corp (0.50%) and Echo Street Capital Management LLC (0.33%). Company insiders that own Bolt Biotherapeutics stock include Edgar Engleman, Randall C Schatzman, Vivo Capital Fund Viii, LP and William P Quinn.
View institutional ownership trends for Bolt Biotherapeutics
.

Which institutional investors are selling Bolt Biotherapeutics stock?

BOLT stock was sold by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, Goldman Sachs Group Inc., Vanguard Group Inc., BlackRock Inc., Qube Research & Technologies Ltd, and Northern Trust Corp.
View insider buying and selling activity for Bolt Biotherapeutics
or view top insider-selling stocks.

Which institutional investors are buying Bolt Biotherapeutics stock?

BOLT stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Echo Street Capital Management LLC, GSA Capital Partners LLP, PDT Partners LLC, and Bank of New York Mellon Corp. Company insiders that have bought Bolt Biotherapeutics stock in the last two years include Edgar Engleman, Randall C Schatzman, Vivo Capital Fund Viii, LP, and William P Quinn.
View insider buying and selling activity for Bolt Biotherapeutics
or or view top insider-buying stocks.

How do I buy shares of Bolt Biotherapeutics?

Shares of BOLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bolt Biotherapeutics' stock price today?

One share of BOLT stock can currently be purchased for approximately $1.64.

How much money does Bolt Biotherapeutics make?

Bolt Biotherapeutics has a market capitalization of $61.45 million and generates $1.26 million in revenue each year. The company earns $-98.59 million in net income (profit) each year or ($2.64) on an earnings per share basis.

How many employees does Bolt Biotherapeutics have?

Bolt Biotherapeutics employs 91 workers across the globe.

What is Bolt Biotherapeutics' official website?

The official website for Bolt Biotherapeutics is www.boltbio.com.

How can I contact Bolt Biotherapeutics?

Bolt Biotherapeutics' mailing address is 900 CHESAPEAKE DRIVE, REDWOOD CITY CA, 94063. The company can be reached via phone at 650-665-9295 or via email at [email protected].

This page was last updated on 5/19/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.